Breast Cancer: Evaluation of Response to Neoadjuvant Chemotherapy with 3.0-T MR Imaging
Authors:
- Jeon-Hor ChenJeon-Hor Chen
- Shadfar BahriSBShadfar Bahri
- Rita S. MehtaRMRita S. Mehta
- Aida KuzucanAKAida Kuzucan
- Hon J. YuHYHon J. Yu
- Philip M. CarpenterPCPhilip M. Carpenter
- Stephen A. FeigSFStephen A. Feig
- Muqing LinMLMuqing Lin
- David J. B. HsiangDHDavid J. B. Hsiang
- Karen T. LaneKLKaren T. Lane
- John A. ButlerJBJohn A. Butler
- Orhan NalciogluONOrhan Nalcioglu
- 1 December 2011
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 261 (3) , 735-743
Abstract
Human epidermal growth factor receptor 2–negative and hormone receptor–positive cancers and lesions manifesting as areas of nonmasslike enhancements are more likely to show residual disease as smal... PurposeTo assess how the molecular biomarker status of a breast cancer, including human epidermal growth factor receptor 2 (HER2), hormone receptors, and the proliferation marker Ki-67 status, affe...Keywords
This publication has 35 references indexed in Scilit:
- Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without BevacizumabAnnals of Surgical Oncology, 2009
- Breast MRI: guidelines from the European Society of Breast ImagingEuropean Radiology, 2008
- Residual specimen cellularity after neoadjuvant chemotherapy for breast cancerBritish Journal of Surgery, 2008
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancerBritish Journal of Cancer, 2008
- Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant TherapyJournal of Clinical Oncology, 2008
- MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapyCancer, 2007
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Annals of Oncology, 2007
- Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinomaBritish Journal of Cancer, 2006
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005